New developments in non-specific and semi-specific immunosuppression in type I diabetes.
Leslie
R D
RD
Department of Diabetes and Metabolism, St. Bartholomew's Hospital, London, UK.
Carotenuto
P
P
Pozzilli
P
P
D000818:Animals; D000961:Antilymphocyte Serum / Q000494:pharmacology; D016572:Cyclosporine / Q000627:therapeutic use; D003921:Diabetes Mellitus, Experimental / Q000276:immunology / Q000517:prevention & control / Q000628:therapy; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology / Q000517:prevention & control* / Q000628:therapy; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D007328:Insulin / Q000008:administration & dosage; D008222:Lymphokines / Q000037:antagonists & inhibitors; D017893:Photopheresis; D011236:Prediabetic State / Q000276:immunology / Q000517:prevention & control / Q000628:therapy
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D007328:Insulin; D008222:Lymphokines; D016572:Cyclosporine